{"id":"prodiax-23-ppsv23","safety":{"commonSideEffects":[{"rate":"20–50%","effect":"Injection site pain, erythema, or swelling"},{"rate":"5–15%","effect":"Fever"},{"rate":"5–10%","effect":"Myalgia or arthralgia"},{"rate":"5–10%","effect":"Headache"},{"rate":"5–10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified capsular polysaccharides from 23 different serotypes of pneumococcus conjugated to a carrier protein or presented as a polysaccharide mixture. Upon administration, it activates both B and T cell responses to generate protective antibodies and cellular immunity against the most common disease-causing pneumococcal strains, reducing the risk of invasive pneumococcal disease.","oneSentence":"PPSV23 is a pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:51.695Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease in adults and children ≥2 years"},{"name":"Prevention of pneumococcal pneumonia and bacteremia"}]},"trialDetails":[{"nctId":"NCT04875858","phase":"PHASE4","title":"Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2021-05-01","conditions":"Pneumococcal Infections","enrollment":254},{"nctId":"NCT04551248","phase":"","title":"Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2021-08-01","conditions":"Pneumococcal Vaccine Adverse Reaction","enrollment":1000000},{"nctId":"NCT02079207","phase":"PHASE3","title":"Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2013-12","conditions":"Pneumococcal Infections","enrollment":767}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":535,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ProDiax-23 (PPSV23)","genericName":"ProDiax-23 (PPSV23)","companyName":"Korea University Guro Hospital","companyId":"korea-university-guro-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PPSV23 is a pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in adults and children ≥2 years, Prevention of pneumococcal pneumonia and bacteremia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}